Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
The Lancet Regional Health. Western Pacific|July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancerYuankai Shi, Gongyan Chen, Xiang Wang, et al.
The Lancet. Oncology|July 26, 2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
Thoracic Cancer|May 31, 2019
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang, Xia Song, Yuhui Zhang, et al.
Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.
Nature Communications|August 8, 2018
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancerJingying Nong, Yuhua Gong, Yanfang Guan, et al.
Nature Communications|January 31, 2019
Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancerJingying Nong, Yuhua Gong, Yanfang Guan, et al.
BMC Medicine|April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studiesXingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.
Thoracic Cancer|September 26, 2018
Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional studyYing Cheng, Yan Wang, Jun Zhao, et al.
BMC Medicine|February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
The Lancet. Oncology|August 17, 2013
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialYuankai Shi, Li Zhang, Xiaoqing Liu, et al.
Pageof 14